-

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Contacts

Alkermes Contact:
Sandy Coombs
Investor Relations
+1 781 609 6377

Industry:

Alkermes plc

NASDAQ:ALKS
Release Versions
English

Contacts

Alkermes Contact:
Sandy Coombs
Investor Relations
+1 781 609 6377

More News From Alkermes plc

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Based on the positive results demonstrated by alixorexton in the phase 2 Vibrance Studies in NT1 and NT2,...

Alkermes plc Reports Second Quarter 2026 Financial Results

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today, to discuss these financial results and expectations, and provide an update on the company. The webcast ma...

Alkermes to Report Second Quarter Financial Results on July 28, 2026

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company’s second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast...
Back to Newsroom